These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 21257320)

  • 1. Local tolerance and stability up to 24 months of a new 20% proline-stabilized polyclonal immunoglobulin for subcutaneous administration.
    Maeder W; Lieby P; Sebald A; Spycher M; Pedrussio R; Bolli R
    Biologicals; 2011 Jan; 39(1):43-9. PubMed ID: 21257320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions.
    Bolli R; Woodtli K; Bärtschi M; Höfferer L; Lerch P
    Biologicals; 2010 Jan; 38(1):150-7. PubMed ID: 19931468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-proline-stabilized human IgG: Privigen® 10% for intravenous use and Hizentra® 20% for subcutaneous use.
    Berger M
    Immunotherapy; 2011 Feb; 3(2):163-76. PubMed ID: 21322757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stability over 36 months of a new liquid 10% polyclonal immunoglobulin product (IgPro10, Privigen) stabilized with L-proline.
    Cramer M; Frei R; Sebald A; Mazzoletti P; Maeder W
    Vox Sang; 2009 Apr; 96(3):219-25. PubMed ID: 19207169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency.
    Wasserman RL; Melamed I; Nelson RP; Knutsen AP; Fasano MB; Stein MR; Rojavin MA; Church JA
    Clin Pharmacokinet; 2011 Jun; 50(6):405-14. PubMed ID: 21553933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach.
    Jolles S; Sleasman JW
    Adv Ther; 2011 Jul; 28(7):521-33. PubMed ID: 21681653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of solvent environment on the conformation and stability of human polyclonal IgG in solution.
    Szenczi A; Kardos J; Medgyesi GA; Závodszky P
    Biologicals; 2006 Mar; 34(1):5-14. PubMed ID: 16168667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency.
    Hagan JB; Fasano MB; Spector S; Wasserman RL; Melamed I; Rojavin MA; Zenker O; Orange JS
    J Clin Immunol; 2010 Sep; 30(5):734-45. PubMed ID: 20454851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro glycation of human immunoglobulin G.
    Vrdoljak A; Trescec A; Benko B; Hecimovic D; Simic M
    Clin Chim Acta; 2004 Jul; 345(1-2):105-11. PubMed ID: 15193984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of nonionic surfactants on the physical stability of immunoglobulin G in aqueous solution during mechanical agitation.
    Vidanovic D; Milic Askrabic J; Stankovic M; Poprzen V
    Pharmazie; 2003 Jun; 58(6):399-404. PubMed ID: 12857003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of L-proline as a stabilizer for immunoglobulin products.
    Hagan JB; Wasserman RL; Baggish JS; Spycher MO; Berger M; Shashi V; Lohrmann E; Sullivan KE
    Expert Rev Clin Immunol; 2012 Feb; 8(2):169-78. PubMed ID: 22288455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Tolerability of Manual Push Administration of Subcutaneous IgPro20 at High Infusion Rates in Patients with Primary Immunodeficiency: Findings from the Manual Push Administration Cohort of the HILO Study.
    Cowan J; Bonagura VR; Lugar PL; Maglione PJ; Patel NC; Vinh DC; Hofmann JH; Praus M; Rojavin MA
    J Clin Immunol; 2021 Jan; 41(1):66-75. PubMed ID: 33025378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new liquid, intravenous immunoglobulin product (IGIV 10%) highly purified by a state-of-the-art process.
    Teschner W; Butterweck HA; Auer W; Muchitsch EM; Weber A; Liu SL; Wah PS; Schwarz HP
    Vox Sang; 2007 Jan; 92(1):42-55. PubMed ID: 17181590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Tolerability of Subcutaneous IgPro20 at High Infusion Parameters in Patients with Primary Immunodeficiency: Findings from the Pump-Assisted Administration Cohorts of the HILO Study.
    Anderson JT; Bonagura VR; Cowan J; Hsu C; Mustafa SS; Patel NC; Routes JM; Sriaroon P; Vinh DC; Hofmann JH; Praus M; Rojavin MA
    J Clin Immunol; 2021 Feb; 41(2):458-469. PubMed ID: 33409867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia.
    Björkander J; Nikoskelainen J; Leibl H; Lanbeck P; Wallvik J; Lumio JT; Braconier JH; Pavlova BG; Birthistle K; Engl W; Walter S; Ehrlich HJ
    Vox Sang; 2006 May; 90(4):286-93. PubMed ID: 16635071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stability of doripenem in vitro in representative infusion solutions and infusion bags.
    Psathas PA; Kuzmission A; Ikeda K; Yasuo S
    Clin Ther; 2008 Nov; 30(11):2075-87. PubMed ID: 19108795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on antigenic competition. I. Antigenic competition between the Fc and Fab fragments of rabbit IgG in mice.
    Taussig MJ
    Immunology; 1971 Jul; 21(1):51-60. PubMed ID: 5558032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home.
    Gardulf A; Nicolay U; Math D; Asensio O; Bernatowska E; Böck A; Costa-Carvalho BT; Granert C; Haag S; Hernández D; Kiessling P; Kus J; Matamoros N; Niehues T; Schmidt S; Schulze I; Borte M
    J Allergy Clin Immunol; 2004 Oct; 114(4):936-42. PubMed ID: 15480339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High concentration formulation feasibility of human immunoglubulin G for subcutaneous administration.
    Dani B; Platz R; Tzannis ST
    J Pharm Sci; 2007 Jun; 96(6):1504-17. PubMed ID: 17387698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
    Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.